Cytomegalovirus Infection Management in Multivisceral and Intestinal Transplant: A Dual Institution Study
Recommended Citation
Currier EE, Ichkanian Y, Dabaja M, Segovia MC, Patel Y, Nagai S, Sudan DL, and Jafri SM. Cytomegalovirus Infection Management in Multivisceral and Intestinal Transplant: A Dual Institution Study. Transplant Proc 2023.
Document Type
Article
Publication Date
2-13-2023
Publication Title
Transplantation proceedings
Abstract
Intestinal transplant and multivisceral transplant were originally in pediatric populations and are relatively new procedures in adults. Despite increasing success rates in the immediate post-transplant period, infectious complications and acute and chronic rejection remain significant causes of morbidity and mortality. Previous research has shown cytomegalovirus (CMV) is the main cause of infection in this population. Due to the limited patient population, incidence of CMV viremia ranges widely and there is lack of universal protocol for treatment. This dual institution retrospective chart review between Henry Ford Hospital and Duke University analyzed adult intestinal and multivisceral transplant recipients between 2009 and 2019. Of the 32 patients identified and included in the study, 15 had CMV infection (46.9%). Of those with CMV infection, 5 (33.3%) had donor positive (D+)/recipient positive (R+) status; 5 had D-/R+; 4 had D+/R-; and one had D-/R-. There was no significant difference between mortality in those who had reported infection and not (80% vs 76.5%). The data from this study show significant rates of CMV viremia in patients undergoing intestinal transplant/multivisceral transplant with almost half of our study population having documented infection within 1 year of transplant, stressing the importance for universal protocol into CMV viremia treatment.
PubMed ID
36792485
ePublication
ePub ahead of print
